Home › Research › Biomarkers
PET Imaging in Alzheimer Disease in the Era of Antiamyloid Therapy in the United States: Clinical Utility, Quantification, and Policy Landscape
Ty J. Skyles, Samantha M. Bouchal, Anna O. Giarratana, Jacob Wengler, Ian R. Hart, Erin E. Greig, Harmanjeet Singh, Steve S. Huang et al.. Journal of Nuclear Medicine Technology, 2026-02-10
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Amyloid PET enables improved detection of amyloid-β plaques within the brain. Amyloid PET is increasingly vital for confirming AD diagnoses given the emergence of antiamyloid immunotherapies, which require biomarker-verified amyloid positivity to initiate treatment. Tau PET provides a direct measure of neurofibrillary tangle pathology and is useful for disease staging, the interpretation of atypical clinical presentations, and treatment decision-making. 18F-FDG PET plays a vital role in distinguishing AD from other dementia subtypes. Expanded reimbursement policies for amyloid and tau PET have increased accessibility to these modalities. Finally, quantitative methods facilitate interscan reproducibility and permit therapeutic monitoring. Molecular neuroimaging is poised to play a central role in the biologic definition, diagnosis, staging, and management of AD. Integrating amyloid, tau, and FDG PET with clinical assessments and fluid biomarkers provides earlier and more accurate diagnoses, opening the door to personalized treatment.
What this study adds
Evidence grade: Low
This review describes how amyloid PET is used to confirm amyloid positivity before starting anti-amyloid immunotherapy, while tau PET helps stage disease and FDG PET helps distinguish Alzheimer's from other dementias. It reports that expanded reimbursement has increased access to these scans, but it presents no new treatment or cure.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Skyles, T. J., Bouchal, S. M., Giarratana, A. O., Wengler, J., Hart, I. R., Greig, E. E., et al. (2026). PET Imaging in Alzheimer Disease in the Era of Antiamyloid Therapy in the United States: Clinical Utility, Quantification, and Policy Landscape. Journal of Nuclear Medicine Technology. https://doi.org/10.2967/jnmt.125.271835
Vancouver
Skyles TJ, Bouchal SM, Giarratana AO, Wengler J, Hart IR, Greig EE, et al. PET Imaging in Alzheimer Disease in the Era of Antiamyloid Therapy in the United States: Clinical Utility, Quantification, and Policy Landscape. Journal of Nuclear Medicine Technology. 2026. doi:10.2967/jnmt.125.271835. PMID: 41667280.
BibTeX
@article{skyles2026-41667280,
author = {Skyles, Ty J. and Bouchal, Samantha M. and Giarratana, Anna O. and Wengler, Jacob and Hart, Ian R. and Greig, Erin E. and Singh, Harmanjeet and Huang, Steve S. and others},
title = {{PET Imaging in Alzheimer Disease in the Era of Antiamyloid Therapy in the United States: Clinical Utility, Quantification, and Policy Landscape}},
journal = {Journal of Nuclear Medicine Technology},
year = {2026},
doi = {10.2967/jnmt.125.271835},
pmid = {41667280},
url = {https://doi.org/10.2967/jnmt.125.271835}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Amyloid PET enables improved detection of amyloid-β plaques within the brain.
- Amyloid PET is increasingly vital for confirming AD diagnoses given the emergence of antiamyloid immunotherapies, which require biomarker-verified amyloid positivity to initiate treatment.
- Tau PET provides a direct measure of neurofibrillary tangle pathology and is useful for disease staging, the interpretation of atypical clinical presentations, and treatment decision-making. 18F-FDG PET plays a vital role in distinguishing AD from other dementia subtypes.
- Expanded reimbursement policies for amyloid and tau PET have increased accessibility to these modalities.
- Finally, quantitative methods facilitate interscan reproducibility and permit therapeutic monitoring.
Why it matters
This review describes how amyloid PET is used to confirm amyloid positivity before starting anti-amyloid immunotherapy, while tau PET helps stage disease and FDG PET helps distinguish Alzheimer's from other dementias. It reports that expanded reimbursement has increased access to these scans, but it presents no new treatment or cure.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 43/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Nuclear Medicine Technology) |
| Journal's citation record | 0 / 4 | Journal of Nuclear Medicine Technology: journal h-index 51 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 7 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 5 / 6 | Cited 33.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Mary Ellen I. Koran: h-index 20 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Mayo Clinic: institution h-index 1,606 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41667280) |
| Free to read | 2 / 2 | Free to read |
| Total | 43 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.2967/jnmt.125.271835
- PubMed: 41667280
- Original source →
- Free full text: Journal of Nuclear Medicine Technology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 25.
Related studies in Biomarkers from nearby years
Also tagged “machine”
834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.